The purpose of this article is to present a selective and concise summary of
fluorodeoxyglucose (FDG) positron emission tomography (PET) in dementia imaging. FDG …

Magnetic resonance-guided focused ultrasound in combination with intravenously injected
microbubbles has been shown to transiently open the blood–brain barrier, and reduce beta …

There is increasing use of neuroimaging modalities, including PET, for diagnosing
dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior …

Cerebrovascular disease is a potential risk factor for Alzheimer's disease (AD). Although
acute cerebral hypoperfusion causes neuronal necrosis and infarction, chronic cerebral …

Objective In vivo glycolysis-related glucose metabolism and electron transport chain-related
mitochondrial activity may be different regionally in the brains of patients with Alzheimer …

Because hypoperfusion of brain tissue precedes atrophy in dementia, the detection of
dementia may be advanced by the use of perfusion information. Such information can be …

The use of Alzheimer's disease (AD) biomarkers is supported in diagnostic criteria, but their
maturity for clinical routine is still debated. Here, we evaluate brain fluorodeoxyglucose …

To determine how arterial spin labeling (ASL) measured perfusion relates to baseline
metabolism, we compared resting state cerebral perfusion using pseudo-continuous ASL …

Purpose Positron emission tomography (PET) imaging with amyloid-beta (Aβ) tracers and 2-
[18F] fluoro-2-Deoxy-d-glucose (18F-FDG) is extensively employed in Alzheimer's disease …

Objective: We describe the operationalization of the National Institute on Aging-Alzheimer's
Association (NIA-AA) workgroup diagnostic guidelines pertaining to Alzheimer disease (AD) …